14 min listen
Targeting Sickle Cell Disease
ratings:
Length:
15 minutes
Released:
Oct 24, 2022
Format:
Podcast episode
Description
Terri Booker’s body burns with pain. She’s one of the 100,000 Americans living with sickle cell disease – a blood disorder that can cause severe pain, organ failure, and even premature death. The genetic condition came about to protect against malaria. Dr. William Hobbs leads clinical development for sickle cell disease at Vertex – their investigational research into sickle cell disease uses cutting-edge technology. Produced by Bloomberg Media Studios and Vertex Pharmaceuticals. Featured guests:Terri Booker is an attorney and sickle cell advocate based in Philadelphia, Pennsylvania.Dr. Isaac Odame is the Haematology Section Head in the Division of Haematology/Oncology and the Medical Director of the Global Sickle Cell Disease Network at the Centre for Global Child Health at The Hospital for Sick Children.Dr. David Altshuler is the Executive Vice President, Global Research and Chief Scientific Officer at Vertex Pharmaceuticals. William Hobbs is a Vice President leading clinical development into hematology at Vertex Pharmaceuticals.Dr. William Hobbs is the VP- Clinical Development, Hematology at Vertex Pharmaceuticals.Read more about Vertex's approach to targeting sickle cell disease
Released:
Oct 24, 2022
Format:
Podcast episode
Titles in the series (7)
Targeting Cystic Fibrosis: NFL quarterback Boomer Esiason’s career high came just days before his son was diagnosed with cystic fibrosis (CF) – a genetic disease characterized by thick and sticky mucus that interferes with breathing, digestion and the body’s ability to fight infections. Esiason now dedicates his free time to raising awareness to fund the search for a cure. We explore how Vertex’s Chief Scientific Officer, Dr. David Altshuler, and the research team at Vertex have spent the last 20+ years researching the underlying cause of the disease – and their work is not yet finished. Produced by Bloomberg Media Studios and Vertex Pharmaceuticals. by Targeting the Toughest Diseases